We demonstrate that, in a model of hepatocarcinogenesis resembling human non-alcoholic fatty liver disease, Nrf2 mutations are the earliest molecular changes responsible for the activation of the Nrf2-Keap1 pathway. This evidence concerns the gene NFE2L2 and metabolic dysfunction-associated steatotic liver disease.